Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03486067
Recruitment Status : Recruiting
First Posted : April 3, 2018
Last Update Posted : August 3, 2022
Sponsor:
Information provided by (Responsible Party):
Celgene

Brief Summary:
Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: CC-93269 Phase 1

Detailed Description:
The dose escalation parts (Part A with CC-93269 administered intravenous (IV) and Part C subcutaneous (SC)) of the study will evaluate the safety and tolerability of escalating doses of CC-93269, administered IV or SC, to determine the maximum tolerated dose (MTD) and non-tolerated dose (NTD) of CC-93269. The expansion parts (Part B and D) will further evaluate the safety and efficacy of CC-93269 administered IV or SC at or below the MTD in selected expansion cohorts of up to approximately 20 evaluable subjects each in order to determine the Recommended Phase 2 dose (RP2D).One or more dosing regimens may be selected for cohort expansion. All treatments will be administered in 28-day cycles for up to 2 years or extended up to 5 years for subjects maintaining clinical benefit at the discretion of the Safety Review Committee, until confirmed disease progression, unacceptable toxicity, or subject/investigator decision to withdraw.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 220 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
Actual Study Start Date : April 3, 2018
Estimated Primary Completion Date : July 26, 2027
Estimated Study Completion Date : August 30, 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: Administration of CC-93269 Drug: CC-93269
Specified dose on specified days
Other Name: Alnuctamab




Primary Outcome Measures :
  1. Adverse Events (AEs) [ Time Frame: Up to 60 months ]
    Number of participants with Adverse Events

  2. Dose Limiting Toxicity (DLT) [ Time Frame: Up to 60 months ]
    Is defined as any of the toxicities occurring within the DLT assessment window (Cycle 1, Days 1 to 28) except those that are clearly and incontrovertibly due to extraneous causes.

  3. Non-Tolerated Dose (NTD) [ Time Frame: Up to 60 months ]
    Is defined as a dose level at which 2 or more of up to 6 evaluable subjects in any dose cohort experience a DLT in the DLT window.

  4. Maximum Tolerated Dose (MTD) [ Time Frame: Up to 60 months ]
    Is defined as the last dose cohort below the NTD with 0 or 1 out of 6 evaluable subjects experiencing a DLT during the DLT window.


Secondary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: Up to 60 months ]
    Is defined as the proportion of subjects who achieve a partial response or better (eg, PR, VGPR, CR or sCR), according to International Myeloma Working Group (IMWG) response criteria.

  2. Time to Response [ Time Frame: Up to 60 months ]
    Is defined as the time from the first CC-93269 dose date to the date of first documented response (PR or better).

  3. Duration of Response [ Time Frame: Up to 60 months ]
    Is defined as the time from the earliest date of documented response (≥ PR) to the first documented disease progression or death, whichever occurs first.

  4. Progression Free Survival [ Time Frame: Up to 60 months ]
    Is defined as the time from the first dose of CC-93269 to progressive disease or death from any cause, whichever occurs first.

  5. Overall Survival [ Time Frame: Up to 60 months ]
    Is defined as the time from the first dose of CC-93269 to death from any cause.

  6. Pharmacokinetics - Cmax [ Time Frame: Up to 60 months ]
    Maximum serum concentration of drug

  7. Pharmacokinetics - Cmin [ Time Frame: Up to 60 months ]
    Minimum serum concentration of drug

  8. Pharmacokinetics - AUC [ Time Frame: Up to 60 months ]
    Area under the curve

  9. Pharmacokinetics - tmax [ Time Frame: Up to 60 months ]
    Time to peak (maximum) serum concentration

  10. Pharmacokinetics - t1/2 [ Time Frame: Up to 60 months ]
    Terminal Half-life

  11. Pharmacokinetics - CL [ Time Frame: Up to 60 months ]
    Apparent total body clearance

  12. Pharmacokinetics - Vss [ Time Frame: Up to 60 months ]
    Volume of distribution at steady-state

  13. Pharmacokinetics - accumulation index of alnuctamab [ Time Frame: Up to 60 months ]
    Accumulation ratio of drug

  14. Presence and frequency of anti-drug antibodies (ADA) [ Time Frame: Up to 60 months ]
    Detection of anti-drug antibodies in participants and frequency of anti-drug antibodies

  15. Evaluate measures of tumor sensitivity/ resistance to CC-93269 [ Time Frame: Up to 60 months ]
    Measurement of tumor and immune factors



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of multiple myeloma with relapsed and refractory disease
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1
  • Must have measurable disease as determined by the central laboratory

Exclusion Criteria:

  • Symptomatic central nervous system involvement of multiple myeloma
  • Prior autologous stem cell transplant ≤ 3 months prior
  • Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 12 months prior
  • History of concurrent second cancers requiring active, ongoing systemic treatment

Other protocol-defined inclusion/exclusion criteria apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03486067


Contacts
Layout table for location contacts
Contact: BMS Study Connect Contact Center www.BMSStudyConnect.com 855-907-3286 Clinical.Trials@bms.com
Contact: First line of the email MUST contain the NCT# and Site #.

Locations
Show Show 28 study locations
Sponsors and Collaborators
Celgene
Investigators
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Additional Information:
Layout table for additonal information
Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT03486067    
Other Study ID Numbers: CC-93269-MM-001
U1111-1210-6325 ( Registry Identifier: WHO )
2017-003448-19 ( EudraCT Number )
First Posted: April 3, 2018    Key Record Dates
Last Update Posted: August 3, 2022
Last Verified: August 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Celgene:
Multiple Myeloma
BCMA X CD3 T Cell
Antibody
CC-93269
Relapsed and Refractory
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases